The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Cured of Hepatitis C: Is There Potential to Infect Others?

Back to News Homepage

Next

Telling a Child He or She Is Infected with Hepatitis C

Supplemental New Drug Application Submitted to FDA by Janssen

July 22, 2014

Print this page

Find out about Janssen’s goal for Olysio to be used once-daily in combination with Sovaldi.

ISSUE: JULY 2014

Janssen Submits Supplemental NDA For Olysio for Once-Daily Use In Combination With Sofosbuvir

On May 7, Janssen announced the submission of a Supplemental New Drug Application (sNDA) to the FDA for simeprevir (Olysio), an NS3/4A hepatitis C virus (HCV) protease inhibitor, in combination with the NS5B HCV polymerase inhibitor, sofosbuvir (Sovaldi, Gilead Sciences). Janssen is seeking regulatory approval of the combination for the treatment of HCV genotype 1 infection in treatment-naive patients with advanced liver fibrosis and in null responders with all stages of liver fibrosis.

Continue reading this entire article:
http://www.idse.net/ViewArticle.aspx?d=Hepatitis&d_id=213&i=July+2014&i_id=1086&a_id=27752

3 Comments
Share
Share

Previous

Cured of Hepatitis C: Is There Potential to Infect Others?

Back to News Homepage

Next

Telling a Child He or She Is Infected with Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.